1-18 of 18
Rachel Koldej
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A- rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial

Sun Loo, Harry Iland, Ing Soo Tiong, David Westerman, Jad Othman, Paula Marlton, Chong Chyn Chua, Duncan Purtill, Hannah Rose, Shaun Fleming, Deepak Singhal, Anoop K Enjeti, William S. Stevenson, Teng Fong Ng, McCulloch Derek, Lachlin Vaughan, Robin Gasiorowski, Adam Ivey, Amanda Souza, Revati Pattani, Natasha S. Anstee, Rachel Koldej, David S. Ritchie, Sanam Loghavi, Naval Daver, Courtney D. DiNardo, Andrew W. Roberts, Carolyn S. Grove, John Reynolds, Andrew H Wei
Journal: Blood
Blood (2024) 144 (Supplement 1): 223.
https://doi.org/10.1182/blood-2024-202895
Published: 2024
Journal Articles

A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial

Chong Chyn Chua, Blake Hsu, Anoop K Enjeti, Ashish Bajel, Paula Marlton, Shaun Fleming, Devendra Hiwase, Chun Kei Kris Ma, Peter J. Browett, Travis Perera, Carolyn S. Grove, Shuhying Tan, Jad Othman, Julian Cooney, Hannah Rose, Edward S Morris, Rachel Koldej, David S. Ritchie, Kate Mason, Natasha S. Anstee, John Reynolds, Andrew H Wei
Journal: Blood
Blood (2024) 144 (Supplement 1): 217.
https://doi.org/10.1182/blood-2024-199882
Published: 2024
Journal Articles

Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment

Joanne Elizabeth Davis, Lina HH Le, Mandy Ludford-Menting, Nicholas Holzwart, Sasanka M Handunnetti, Constantine S. Tam, Mary Ann Anderson, David S. Ritchie, Rachel Koldej
Journal: Blood
Blood (2024) 144 (Supplement 1): 4384.
https://doi.org/10.1182/blood-2024-199866
Published: 2024
Journal Articles

T Cell CD62L Expression Following Nivolumab Therapy Is Associated with Long Term Response to Rituximab-Nivolumab in Treatment Naïve Follicular Lymphoma: Results from the 1 st FLOR Study

Rachel Koldej, Allison Barraclough, Sze Ting Lee, Huw Morgan, Nicholas Holzwart, Minu Koshy, Charmaine Smith, Geoffrey Chong, Michael Gilbertson, Colm Keane, Denise Lee, Leonid Churilov, David S. Ritchie, Eliza A. Hawkes
Journal: Blood
Blood (2024) 144 (Supplement 1): 4376.
https://doi.org/10.1182/blood-2024-199854
Published: 2024
Journal Articles

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

Clinical Trials & Observations Brief Report
Sasanka M. Handunnetti, Mary Ann Anderson, Kate Burbury, Philip A. Thompson, Glenda Burke, Mathias Bressel, Juliana Di Iulio, Rodney J. Hicks, David Westerman, Stephen Lade, Christiane Pott, Rishu Agarwal, Rachel Koldej, David Ritchie, Martin Dreyling, Mark A. Dawson, Sarah-Jane Dawson, John F. Seymour, Andrew W. Roberts, Constantine S. Tam
Journal: Blood
Blood (2024) 144 (8): 867–872.
https://doi.org/10.1182/blood.2023023388
Published: 2024
Includes: Supplemental data
Journal Articles

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

Clinical Trials & Observations
Adrian Minson, Nada Hamad, Chan Y. Cheah, Constantine Tam, Piers Blombery, David Westerman, David Ritchie, Huw Morgan, Nicholas Holzwart, Stephen Lade, Mary Ann Anderson, Amit Khot, John F. Seymour, Molly Robertson, Imogen Caldwell, Georgina Ryland, Javad Saghebi, Zahra Sabahi, Jing Xie, Rachel Koldej, Michael Dickinson
Journal: Blood
Blood (2024) 143 (8): 673–684.
https://doi.org/10.1182/blood.2023021306
Published: 2024
Includes: Supplemental data
Journal Articles

Lower Cumulative Incidence of Relapse but Higher Incidence of NRM in Patients with Poor Graft Function Following Allogeneic Stem Cell Transplantation

Ashvind Prabahran, Rachel Koldej, Lynette C.Y. Chee, David S. Ritchie
Journal: Blood
Blood (2023) 142 (Supplement 1): 4912.
https://doi.org/10.1182/blood-2023-190941
Published: 2023
Journal Articles

Clinical Determinants of T-Cell Receptor Diversity after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

David Ritchie, MD PhD, Eric Wong, MD, Rachel Koldej, James Anton Kuzich, Piers Blombery, MBBS, Georgina L Ryland, Yamuna Kankanige, Jerick Guinto
Journal: Blood
Blood (2019) 134 (Supplement_1): 1997.
https://doi.org/10.1182/blood-2019-129308
Published: 2019
Journal Articles

Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers

Joanne Davis, PhD, Sasanka M Handunnetti, MBBS, Chia Sharpe, Gillian Turner, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD FRACP, Constantine S. Tam, MBBS, MD, David Ritchie, MD PhD, Rachel Koldej
Journal: Blood
Blood (2019) 134 (Supplement_1): 2791.
https://doi.org/10.1182/blood-2019-122974
Published: 2019
Journal Articles

Recipient Age and Marked Thrombocytopenia Are Associated with Increased Mortality in Patients with Poor Graft Function Post Allogeneic Transplantation

Ashvind Prabahran, MBBS, David Ritchie, MD PhD, Lynette C.Y. Chee, Rachel Koldej
Journal: Blood
Blood (2019) 134 (Supplement_1): 4512.
https://doi.org/10.1182/blood-2019-132046
Published: 2019
Journal Articles

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

Eliza A Hawkes, Kate Manos, Geoff Chong, Jodie Palmer, Michael MacManus, Colm Keane, MD, Andrew Scott, Jake Shortt, MBBS FRACP FRCPA PhD, David Ritchie, MD PhD, Leonid Churilov, Laura Johnston, Tom Witkowski, Allison Barraclough, Sze-Ting Lee, Wendi Lin, Rachel Koldej, Richard Khor
Journal: Blood
Blood (2019) 134 (Supplement_1): 5328.
https://doi.org/10.1182/blood-2019-122635
Published: 2019
Journal Articles

Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1 st FLOR' Study

Allison Barraclough, Geoff Chong, Michael Gilbertson, Andrew Grigg, Leonid Churilov, Tineke Fancourt, David Ritchie, MD PhD, Rachel Koldej, Rishu Agarwal, Kate Manos, Charmaine Smith, Kristen Houdyk, Joanne Hawking, Eliza Hawkes
Journal: Blood
Blood (2019) 134 (Supplement_1): 1523.
https://doi.org/10.1182/blood-2019-123908
Published: 2019
Journal Articles

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Rishu Agarwal, Mark A. Dawson, PhD MBBS, Sarah-Jane Dawson, MD PhD, Rachel Koldej, David Ritchie, MD PhD, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Constantine S. Tam, MBBS, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 756.
https://doi.org/10.1182/blood-2019-126619
Published: 2019
Journal Articles

More Than a BTK Inhibitor; Ibrutinib Profoundly Impacts the Function of Cell Mediated Immunity

Chia Sharpe, Joanne Davis, PhD, Kylie D. Mason, MBBS, MD FRACP, FRCPA, PhD, Dale I Godfrey, PhD, Adam Uldrich, PhD, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Rachel Koldej, PhD, David Ritchie, MBChB, PhD FRACP, FRCPA
Journal: Blood
Blood (2018) 132 (Supplement 1): 4417.
https://doi.org/10.1182/blood-2018-99-117618
Published: 2018
Journal Articles

CD4 + T Cell Fate in Multiple Myeloma

Rachel Elizabeth Cooke, BSc, FRACP, FRCPA, MBBS, Jessica Chung, PhD, Sarah Gabriel, PhD, Hang Quach, MD FRACP, FRCPA, MBBS, Simon J. Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, H. Miles Prince, MD FRACP, FRCPA, Rachel Koldej, PhD, David Ritchie, MBChB, PhD FRACP, FRCPA
Journal: Blood
Blood (2018) 132 (Supplement 1): 4494.
https://doi.org/10.1182/blood-2018-99-117674
Published: 2018
Journal Articles

Nivolumab for Relapsed or Residual Haematological Malignancies after Allogeneic Haematopoietic Stem Cell Transplantation (NIVALLO)

Eric Wong, MBBS, Emily Dawson, Joanne Davis, PhD, Rachel Koldej, PhD, Mandy Ludford-Menting, Matthew Lansdown, Heather Lambie, Jeffrey Szer, MBBS, Andrew P. Grigg, MBBS, FRACP, FRCPA, MD, David Ritchie, MBChB, PhD FRACP, FRCPA
Journal: Blood
Blood (2018) 132 (Supplement 1): 4633.
https://doi.org/10.1182/blood-2018-99-112310
Published: 2018
Journal Articles

Natural Killer Receptor Ligand Expression By AML Blasts Determines Survival and Relapse Following Induction Chemotherapy

Sara Mastaglio, MD, Eric Wong, MD, Travis Perera, Ripley Jane, Piers Blombery, MBBS, Rachel Koldej, David Ritchie, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3948.
https://doi.org/10.1182/blood.V130.Suppl_1.3948.3948
Published: 2017
Journal Articles

A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation and Onset of Gvhd

Joanne E Davis, PhD, Michael Harvey, BSc(Hons), Nicholas A Gherardin, BSc(Hons), Rachel Koldej, PhD, Nicholas Huntington, PhD, Paul Neeson, PhD, Joseph A Trapani, PhD MBBS, FRACP, David Ritchie, MBBS, PhD FRACP, FRCPA
Journal: Blood
Blood (2014) 124 (21): 3805.
https://doi.org/10.1182/blood.V124.21.3805.3805
Published: 2014